IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.